Dyrene

Dyrene

SCHEMBL504140

CCCCCC(CC)(CC)Oc1ccccc1O.COc1ccccc1O.Clc1nc(Cl)nc(Nc2ccccc2Cl)n1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TSHR P16473 4/20 0.44
NPSR1 Q6W5P4 1/20 0.43
GBA1 P04062 1/20 0.40
CNR1 P21554 2/20 0.36
CNR2 P34972 2/20 0.36
GAA P10253 1/20 0.34
RAD52 P43351 2/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
LRRK2 Q5S007 1/20 0.34
PTK2 Q05397 1/20 0.34
HPGD P15428 2/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dyrene SCHEMBL4937195 0.96 TSHR (0.48) MAPTALDH1A1KDM4EKMT2ASMN1; SMN2
Dyrene SCHEMBL7551920 0.86 MAPT (0.45) MAPTALDH1A1KDM4EKMT2ASMN1; SMN2
Dyrene SCHEMBL7191646 0.84 MAPT (0.50) MAPTALDH1A1KDM4EKMT2ASMN1; SMN2
Dyrene SCHEMBL5483770 0.84 MAPT (0.50) MAPTALDH1A1KDM4EKMT2ASMN1; SMN2
Dyrene SCHEMBL1029356 0.83 MAPT (0.65) MAPTALDH1A1KDM4EKMT2ASMN1; SMN2
Guaiacol SCHEMBL1907793 0.81 TP53 (0.51) MAPTALDH1A1KDM4ETSHRCNR1
Dyrene SCHEMBL1029941 0.80 MAPT (0.46) MAPTALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL148644 0.76 CNR1 (0.45) MAPTTSHRCNR1CNR2GAA
Dyrene SCHEMBL8178116 0.75 TSHR (0.75) MAPTALDH1A1KDM4EKMT2ASMN1; SMN2
Dyrene SCHEMBL16113661 0.72 TSHR (0.80) MAPTALDH1A1KDM4EKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 704 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240173229-A1 METHODS OF SKIN WHITENING BY USE OF CANOLA EXTRACTS 1242753 ONTARIO INC (CA) 2024-05-30 US claimed
US-11878070-B2 Silk-based moisturizer compositions and methods thereof EVOLVED BY NATURE, INC. (US) 2024-01-23 US claimed
US-20230398050-A1 STABLE WASH COMPOSITION CONOPCO, INC., D/B/A UNILEVER (US) 2023-12-14 US claimed
EP-4223279-A1 METHODS OF SKIN WHITENENING BY USE OF CANOLA EXTRACTS 1242753 Ontario Inc. (CA) 2023-08-09 EP claimed
CN-114886796-A Silk-based moisturizer composition and method thereof 丝绸医疗公司 2022-08-12 CN claimed
US-20210000704-A1 COSMETIC COMPOSITIONS USING TITANIUM DIOXIDE PARTICLES FOR IR PROTECTION KOBO PRODUCTS, INC. (US) 2021-01-07 US claimed
EP-3288528-B1 SILK-BASED MOISTURIZER COMPOSITIONS AND METHODS THEREOF EVOLVED BY NATURE INC (US) 2020-12-30 EP claimed
EP-3307395-B1 SOLUBILISING AGENTS FOR UV SCREENING COMPOUNDS ISP INVESTMENTS LLC (US) 2020-08-05 EP claimed
US-10729625-B2 Self adapting polymers for anhydrous sunscreen formulations ISP INVESTMENTS LLC (US) 2020-08-04 US claimed
CN-111093601-A Cosmetic compositions for IR protection using titanium dioxide particles 科博产品有限公司 2020-05-01 CN claimed
US-20050019280-A1 Compositions containing phenethyl aryl esters as solubilizing agents for active organic compounds ISP INVESTMENTS LLC 2005-01-27 US claimed
EP-1463482-A1 PHOTOSTABLE SUNSCREEN COMPOSITIONS AND METHODS OF STBAILIZING AVON PRODUCTS, INC. (US) 2004-10-06 EP claimed
US-20030191154-A1 Anhydrous insect repellent composition CITIBANK, N.A., LONDON BRANCH 2003-10-09 US claimed
US-20030124070-A1 Photostable sunscreen compositions and methods of stabilizing AVON PRODUCTS INC. 2003-07-03 US claimed
EP-1323410-A2 Sunscreen emulsion composition and method of use AVON PRODUCTS, INC. (US) 2003-07-02 EP claimed
WO-2003051318-A1 PHOTOSTABLE SUNSCREEN COMPOSITIONS AND METHODS OF STBAILIZING AVON PRODUCTS, INC. (US) 2003-06-26 WO claimed
US-6555095-B1 Containing a compound: L-A-H and A-L-H, wherein L is a lipophilic moiety, wherein A is an aromatic moiety having an ultraviolet absorption maximum between 290 nanometers and 400 nanometers, and wherein H is a hydrophilic moiety AVON PRODUCTS, INC. 2003-04-29 US claimed
US-6531118-B1 Topical compositions with a reversible photochromic ingredient AVON PRODUCTS, INC. 2003-03-11 US claimed
US-6517816-B1 Inner discontinuous phase and an outer continuous phase AVON PRODUCTS, INC. 2003-02-11 US claimed
US-6440402-B1 Photostable sunscreen compositions and methods of stabilizing AVON PRODUCTS, INC. 2002-08-27 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191154-A1 Anhydrous insect repellent composition CUTA, FAAH, ACHE MAPT 602/4885ALDH1A1 286/4885KDM4E 12/4885
US-20030124070-A1 Photostable sunscreen compositions and methods of stabilizing GLA, LAGE3, CYP51A1 MAPT 895/4885ALDH1A1 992/4885KDM4E 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.